Organic nitrates have been the cornerstone of angina management since Brunton first described the relief of anginal symptoms with amyl nitrite in 1867,1 and since Murrell established sublingual nitroglycerin in clinical practice in 1879.2 Despite over 140 years of use, nitrates remain pharmacologically indispensable; no other class combines speed of onset, ease of administration, and reliable preload reduction in a single agent.5 Yet nitrates are also among the most frequently misused drugs in cardiology: tolerance develops predictably, the nitrate-free interval is routinely omitted, contraindications are missed, and the distinction between hemodynamic actions at different doses is rarely exploited deliberately.5·13
This module covers the complete pharmacology of organic nitrates: molecular mechanism, dose-dependent hemodynamic effects, pharmacokinetic differences across formulations, clinical indications, tolerance physiology and management, and the full adverse effect and interaction profile.
Organic nitrates are prodrugs that require bioactivation to release nitric oxide (NO) or a related NO-equivalent species.3 The key enzymatic step is denitration by mitochondrial aldehyde dehydrogenase 2 (ALDH2), which converts nitroglycerin (GTN) and isosorbide dinitrate (ISDN) to inorganic nitrite and then to NO.4 Isosorbide mononitrate (ISMN), the active metabolite of ISDN, does not require denitration; it is already partially activated, undergoing further metabolism to release NO via non-ALDH2 pathways.5 The ALDH2 pathway is clinically important for two reasons: ALDH2 is the enzyme inhibited by disulfiram, explaining drug interactions with alcohol-sensitizing medications; and ALDH2 is the enzyme that becomes inactivated during nitrate tolerance.3·4
Once released, NO diffuses freely into vascular smooth muscle cells and activates soluble guanylyl cyclase (sGC), converting GTP to cyclic GMP (cGMP).3 cGMP activates protein kinase G (PKG), which phosphorylates myosin light chain kinase (MLCK) and reduces its activity. The resulting decrease in myosin light chain phosphorylation causes smooth muscle relaxation and vasodilation.3 Additional downstream effects of elevated cGMP include activation of large-conductance calcium-activated K+ channels (BKCa) leading to membrane hyperpolarization, voltage-gated Ca2+ channel closure, and reduced intracellular Ca2+.3 This cascade is identical to the mechanism of endogenous NO produced by endothelial NO synthase (eNOS); organic nitrates effectively supplement or replace endothelial NO production, which is deficient in atherosclerotic and dysfunctional vessels.11
Nitrates are not equipotent across all vascular beds; their selectivity is dose-dependent.5 At low and standard doses, large capacitance veins dilate predominantly, pooling blood in the peripheral venous system. Reduced venous return leads to decreased right atrial pressure, left ventricular end-diastolic pressure (LVEDP), and ventricular volume, producing preload reduction. The mechanism of anti-ischemic benefit is reduced wall stress, reduced myocardial oxygen consumption (MVO2), reduced subendocardial compressive forces, and improved subendocardial perfusion.5 At higher doses, progressive arterial dilation is added: peripheral arteriolar resistance decreases, producing afterload reduction. IV NTG at rates >50-100 mcg/min contributes meaningfully to afterload reduction, which is relevant in acute decompensated HF.6 Coronary vasodilation is present at all doses: nitrates are potent dilators of epicardial coronary arteries, largely independent of stenosis severity.8 This is the critical mechanism in vasospastic angina: GTN 0.4 mg SL reliably terminates Prinzmetal attacks within 1-3 minutes.8 Nitrates do NOT consistently dilate coronary resistance vessels (microvasculature): limited benefit in microvascular angina; possible coronary steal risk with IV NTG in complex CAD at higher doses.5 Exogenous NO also inhibits platelet aggregation by elevating cGMP in platelets and reduces expression of adhesion molecules on endothelium; these are modest effects compared with antiplatelet drugs but potentially clinically contributory.3
The clinical utility of nitrates depends entirely on matching the right formulation to the clinical purpose.5 The key pharmacokinetic variable is the avoidance of first-pass hepatic metabolism, which is near-complete (~99%) for orally swallowed nitroglycerin.5
Available as 0.3 mg, 0.4 mg, 0.6 mg tablets and 0.4 mg spray. The sublingual route allows direct absorption into the systemic circulation, bypassing hepatic first-pass metabolism. Onset is 1-3 minutes, peak effect at 5 minutes, duration 20-30 minutes, bioavailability ~80%, and half-life 1-4 minutes (reflecting rapid redistribution and metabolism once absorbed).5 Clinical use: acute angina relief. One dose at onset of symptoms; may repeat every 5 minutes, up to 3 doses, if no relief; if no relief after 15 minutes: activate emergency services for possible ACS.9·10 One dose 5 minutes before anticipated activity provides pre-exertional prophylaxis. Practical notes: tablets lose potency with heat, moisture, and light; store in the original glass bottle. The burning sensation under the tongue is a sign of potency (some patients discard active tablets thinking they are defective). The spray formulation has a longer shelf life and may be easier for elderly patients. The patient should sit or lie down before use to minimize hypotension-related syncope.5
Available as 5-40 mg tablets and sublingual 5 mg tablets. Bioavailability (oral): ~25% due to significant first-pass metabolism to active metabolites (2-mononitrate and 5-mononitrate). Onset (oral): 30-60 minutes. Duration: 4-6 hours. Half-life: ~1 hour (parent); active metabolites 2-5 hours.5 Clinical use: chronic prophylaxis of stable angina. Eccentric dosing schedules are required to allow a nitrate-free interval, typically:7 AM and 1 PM (NOT 7 AM and 7 PM, which would eliminate the overnight nitrate-free interval).13 ISDN's variable bioavailability and twice-daily dosing complexity have largely been supplanted by mononitrate formulations in chronic therapy.5
Available as immediate-release (IR) 10 mg and 20 mg tablets, and extended-release (ER) 30 mg, 60 mg, and 120 mg tablets (once-daily dosing). Bioavailability is approximately 100%; there is no significant first-pass metabolism; this is the primary pharmacokinetic advantage over ISDN.5 Half-life: ~5 hours (IR). Onset (IR): 30-60 minutes. Duration (IR): 6-8 hours. Isosorbide mononitrate immediate-release (ISMN-IR) eccentric dosing:7 AM and 2 PM (the 8-hour interval provides an adequate nitrate-free period from approximately 2 PM onwards). Isosorbide mononitrate extended-release (ISMN-ER) once-daily: delivers coverage during waking hours while permitting an overnight nitrate-free interval; take at 7 AM.5 Clinical use: preferred oral nitrate for most outpatient stable angina management. ISMN-ER (once-daily) has the best adherence profile.5 Not suitable for acute symptom relief (too slow onset). ISMN does not require hepatic conversion, so patients with hepatic impairment generally tolerate ISMN without dose adjustment for hepatic reasons.5
Available in 0.1, 0.2, 0.4, and 0.6 mg/hour release rate patches applied for 12-14 hours. Onset: 30-60 minutes after application. Duration: 12-14 hours per patch. Bioavailability: ~75% transdermally.5 The nitrate-free interval is CRITICAL: patches must be removed for 10-12 hours daily (typically at bedtime or early evening). "Wear 12 hours, off 12 hours" is the standard instruction. Failure to remove patches causes continuous nitrate exposure leading to tolerance development within 24-48 hours and rendering the patch ineffective.13 This is one of the most common errors in outpatient nitrate prescribing. Rotation of application sites reduces local skin irritation. NTG patches must be removed before cardioversion or defibrillation due to the risk of skin arcing and burns from the foil backing.5
Intravenous nitroglycerin (IV-NTG) is available as 5 mg/mL concentrate for dilution and premixed solutions 100-400 mcg/mL. Non-premature ventricular contraction (PVC) tubing must be used because NTG adsorbs to PVC, significantly reducing the delivered dose.5 Onset: immediate (within 1-2 minutes). Duration: terminates within 3-5 minutes of stopping infusion. Dosing: start 5-10 mcg/min; titrate by 5-10 mcg/min every 3-5 minutes; typical range 10-200 mcg/min.7·9 Clinical use in hospital settings includes: unstable angina/NSTEMI (symptom control while awaiting revascularization; hemodynamic stabilization);9 acute decompensated heart failure (rapid preload and afterload reduction; superior to furosemide alone in normotensive acute HF);6 hypertensive emergency with ACS or pulmonary edema; and perioperative hypertension.7 Tolerance with IV-NTG develops within 24-48 hours of continuous infusion; transition to oral therapy as early as clinically feasible. Daily infusion interruptions when clinically possible help preserve efficacy.13
Sublingual nitroglycerin (SL-NTG) 0.4 mg is the gold-standard acute intervention. Protocol: one tablet/spray under the tongue at onset of symptoms; sit or lie down; repeat every 5 minutes if no relief; if no relief after 3 doses, call emergency services.9·10 Increasing SL-NTG requirement is a warning sign of worsening angina warranting re-evaluation.9·10
Long-acting nitrates reduce anginal frequency and improve exercise tolerance. They do NOT reduce mortality or MI risk in stable CAD; they are purely anti-ischemic and anti-anginal agents.5 Must be combined with HR-reducing agents (beta-blocker or non-dihydropyridine calcium channel blocker (CCB)) to prevent reflex tachycardia. The nitrate-free interval is mandatory for all long-acting formulations.13
SL-NTG terminates acute spasm rapidly via epicardial coronary vasodilation.8 Long-acting nitrates reduce frequency of attacks in combination with CCBs. CCBs remain the preferred class for prevention; nitrates serve as both rescue therapy and adjunctive prophylaxis.8
IV-NTG is recommended for persistent ischemic symptoms, hypertension, or pulmonary congestion in NSTE-ACS (ACC/AHA Class I).9 NOT proven to reduce ACS mortality.9 AVOID in right ventricular (RV) infarction: NTG-induced preload reduction is catastrophic with RV failure; also avoid within 24-48 hours of phosphodiesterase type 5 (PDE5) inhibitor use.12
IV-NTG is among the most effective acute vasodilators for decompensated HF.6 At low dose: preload reduction, reduces pulmonary congestion. At higher dose (>100 mcg/min): afterload reduction, reduces systemic vascular resistance (SVR), increases cardiac output in volume-overloaded states.6 Particularly useful in warm-wet HF phenotype. Combination with loop diuretics is synergistic: NTG reduces filling pressures rapidly while diuretics produce sustained fluid removal.6
Nitrate tolerance is the attenuation of hemodynamic and anti-ischemic effects with continuous or frequent nitrate exposure, developing within 24-48 hours of continuous administration.3·13 Patients and clinicians often misinterpret tolerance as disease progression. Continuous nitrate exposure may also impair endogenous endothelial NO production, a theoretical concern that chronic nitrate use may worsen the vascular biology it is intended to treat.11
Three mechanisms contribute.3·4·11 The primary mechanism is ALDH2 inactivation: GTN bioactivation by ALDH2 generates reactive intermediates (superoxide, peroxynitrite) that oxidatively inactivate ALDH2 itself, reducing ALDH2 activity, reducing NO generation, and producing an attenuated vasodilatory response.4 This is specific to GTN and ISDN (ALDH2-dependent agents). ISMN may have lower tolerance potential by partially bypassing ALDH2, though clinical differences are modest.5 The secondary mechanism is neurohormonal activation (pseudotolerance): nitrate-induced hypotension activates the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system, causing sodium retention, volume expansion, and vasoconstriction that counteract the nitrate effect.3 This is partially reversible by ACE inhibitors or spironolactone. The tertiary mechanism is increased superoxide and reduced NO bioavailability: nitrate use increases vascular superoxide production (possibly via nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation); superoxide reacts with NO to form peroxynitrite, reducing effective NO concentration and directly impairing sGC activity.11
The nitrate-free interval (NFI) is the only reliably effective strategy to prevent and reverse tolerance.13 During the NFI, ALDH2 is regenerated, neurohormonal activation resolves, and vascular sensitivity to nitrates is restored. Formulation-specific NFI strategies are as follows.13 ISMN-IR (twice daily): Dose 1 at 7:00 AM, Dose 2 at 2:00 PM (NOT 7:00 PM), providing an NFI from approximately 5:00 PM to 7:00 AM (~14 hours). ISMN-ER (once daily): dose at 7:00 AM, providing an NFI from approximately 7:00 PM to 7:00 AM (~12 hours). NTG Patch: apply at 7:00-8:00 AM, remove at 7:00-8:00 PM, providing an overnight NFI (~12 hours). ISDN (twice daily eccentric): Dose 1 at 7:00 AM, Dose 2 at 1:00 PM, providing an afternoon/evening/overnight NFI. IV-NTG: daily 8-hour interruption when clinically feasible; transition to oral therapy as soon as possible.
An important clinical caveat regarding morning angina risk: the NFI coincides with overnight/morning hours, the period of highest circadian angina risk (peak sympathetic tone, platelet aggregability, and coronary vasomotor reactivity).5 Management requires ensuring that a beta-blocker or CCB provides continuous non-nitrate anti-ischemic protection during the NFI. Patient education is essential: the NFI is deliberate and protective, not a gap in treatment.13
Headache is the most common adverse effect, affecting ~30-60% of patients at initiation.5 The mechanism is NO-mediated cerebrovascular vasodilation. The headache is throbbing and frontal, beginning within minutes. It diminishes significantly within 1-2 weeks as cephalic tolerance develops faster than hemodynamic tolerance. Acetaminophen provides symptomatic relief. Patients should be explicitly counseled that headache is expected and not a sign of danger; abrupt discontinuation due to headache is a common cause of subtherapeutic nitrate use.5
Orthostatic hypotension occurs particularly with the first SL-NTG dose.5 Risk factors include hypovolemia, concurrent vasodilators, alcohol, PDE5 inhibitor use, and RV infarction. Patients should be instructed to be seated or supine before SL-NTG. Reflex tachycardia is baroreceptor-mediated, increases MVO2, and partially negates anti-ischemic benefit. It requires a concurrent beta-blocker or non-dihydropyridine CCB to abolish.5·13
Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil, avanafil) prevent breakdown of cGMP. Nitrates increase cGMP via the NO-sGC pathway. The combined effect produces profoundly potentiated vasodilation leading to severe, potentially fatal hypotension.12 Nitrates are ABSOLUTELY CONTRAINDICATED within 24 hours of sildenafil or vardenafil, and within 48 hours of tadalafil (longer half-life). This applies to ALL nitrate formulations including SL-NTG in the emergency department.12 In the clinical scenario where a patient who used a PDE5 inhibitor earlier that day presents to the ED with chest pain: direct questioning about PDE5 inhibitor use is mandatory before any nitrate administration. If taken within the time window, use morphine, IV fluids, and oxygen for ACS pain management and withhold nitrates entirely.12
Organic nitrates oxidize hemoglobin (Fe2+) to methemoglobin (Fe3+), which cannot carry oxygen.5 This is clinically significant at high-dose IV NTG (>5 mcg/kg/min for prolonged periods) or with concurrent oxidizing agents (dapsone, lidocaine, benzocaine). Presentation includes cyanosis unresponsive to supplemental O2 and pulse oximetry reading ~85% regardless of actual saturation (co-oximetry required for diagnosis). Treatment is methylene blue 1-2 mg/kg IV.5
Concurrent PDE5 inhibitor use (within 24-48 hours depending on agent).12 Severe aortic stenosis: preload reduction without ability to increase cardiac output leads to profound hypotension and syncope risk.5 Hypertrophic obstructive cardiomyopathy (HOCM): preload reduction worsens dynamic LVOT obstruction.5 Right ventricular infarction: RV failure is preload-dependent; NTG causes catastrophic hypotension.7·9
Inferior STEMI (high risk of concurrent RV infarction); hypotension (systolic blood pressure (SBP) <90 mmHg); severe bradycardia (<50 bpm) or tachycardia (>110 bpm); hypovolemia; constrictive pericarditis and cardiac tamponade (preload-dependent states).7·9
Beyond the phosphodiesterase-5 inhibitor contraindication, several clinically important drug interactions and physiological interactions affect nitrate safety and efficacy in the outpatient and inpatient settings.5·7
Antihypertensive and vasodilator combinations: Nitrates combined with other antihypertensive agents, particularly dihydropyridine calcium channel blockers, alpha-1 blockers (doxazosin, terazosin, prazosin), and centrally acting agents, produce additive blood pressure reduction.5 This combination is therapeutically appropriate in patients with angina and hypertension but requires careful BP monitoring, particularly on initiation or dose escalation. In elderly patients or those with autonomic dysfunction, the standing BP should be checked before and after adding a nitrate to an existing antihypertensive regimen. The risk of orthostatic hypotension and syncope is highest with the first dose of any new nitrate formulation.5
Alcohol: Ethanol produces peripheral vasodilation and blunts baroreceptor-mediated sympathetic reflexes.5 Concurrent alcohol consumption potentiates nitrate-induced hypotension, particularly with sublingual nitroglycerin, and may precipitate syncope. Patients should be counseled to avoid alcohol for at least two hours after sublingual nitroglycerin use and to sit or lie down after administration regardless.5
Intravenous nitroglycerin and right ventricular infarction: As established in Section 6.1, the right ventricle in acute right ventricular infarction is preload-dependent.10 Intravenous nitroglycerin by reducing venous return collapses right ventricular output and can produce catastrophic hemodynamic deterioration. In clinical practice, any patient with an inferior wall myocardial infarction should have right-sided leads performed before intravenous nitroglycerin is initiated, and the drug should be withheld or discontinued immediately if right ventricular involvement is confirmed.10 Volume resuscitation with 0.9% saline, rather than vasodilation, is the correct management of hypotension in right ventricular infarction.
Heparin interaction with intravenous nitroglycerin: Intravenous nitroglycerin infusion can reduce the anticoagulant effect of unfractionated heparin, requiring higher heparin doses to achieve target activated partial thromboplastin time.7 The mechanism involves nitrate-induced alterations in platelet function and possibly competitive protein binding. When intravenous nitroglycerin is discontinued, heparin requirements may fall and over-anticoagulation can result. Activated partial thromboplastin time should be rechecked within four to six hours of any change in intravenous nitroglycerin infusion rate in patients receiving concurrent unfractionated heparin.7
Ergotamine and triptans: Ergot alkaloids and serotonin 5-HT1B/1D agonists (triptans) produce coronary vasoconstriction and are themselves triggers for vasospastic angina.8 They counteract the vasodilatory mechanism of nitrates and are not safe alternatives in patients who experience nitrate-induced headache. Patients using ergotamine or triptan medications for migraine who develop chest pain should be evaluated for nitrate use with caution, and the potential for drug-induced coronary spasm should be considered in the differential.8
Sublingual NTG: dose 0.3-0.4 mg tablet or 0.4 mg spray; onset 1-3 minutes; duration 20-30 minutes; bioavailability ~80%; indication: acute angina relief and pre-exertional prophylaxis; NFI not needed for PRN use.5 Isosorbide dinitrate (ISDN): dose 10-40 mg twice daily (eccentric dosing); onset 30-60 minutes; duration 4-6 hours; bioavailability ~25%; indication: chronic angina prophylaxis; NFI strategy:7 AM + 1 PM dosing.5 Isosorbide-5-mononitrate (ISMN): IR dose 10-40 mg twice daily (eccentric dosing); ER dose 30-120 mg once daily; onset 30-60 minutes; duration 6-8 hours (IR) or ~12 hours (ER); bioavailability ~100%; indication: chronic angina prophylaxis; NFI strategy: IR at 7 AM + 2 PM, ER at 7 AM.5 Transdermal NTG patch: dose 0.1-0.6 mg/hour; onset 30-60 minutes; duration 12-14 hours per patch; bioavailability ~75%; indication: chronic angina prophylaxis; NFI strategy: apply AM, remove PM (12 on/12 off).5 IV nitroglycerin: dose 5-200 mcg/min (titrate to effect); onset 1-2 minutes; duration 3-5 minutes after stopping; indication: ACS, acute HF, hypertensive emergency; NFI: daily infusion interruption when feasible; note: use non-PVC tubing.7·9
Brunton TL. Use of nitrite of amyl in angina pectoris. Lancet. 1867;2:97-98
doi:10.1016/S0140-6736(02)51392-1Murrell W. Nitroglycerin as a remedy for angina pectoris. Lancet. 1879;1:80-81
doi:10.1016/S0140-6736(02)46032-1Münzel T, Daiber A, Mülsch A. Explaining the phenomenon of nitrate tolerance. Circ Res. 2005;97(7):618-628
doi:10.1161/01.RES.0000184694.03262.6dChen Z, Stamler JS. Bioactivation of nitroglycerin by the mitochondrial aldehyde dehydrogenase. Trends Cardiovasc Med. 2006;16(8):259-265
doi:10.1016/j.yjmcc.2005.12.004Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med. 1998;338(8):520-531
doi:10.1056/NEJM199802193380807Cohn JN, Franciosa JA. Vasodilator therapy of cardiac failure. N Engl J Med. 1977;297(5):254-258
doi:10.1056/NEJM197708042970506Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes. J Am Coll Cardiol. 2014;64(24):e139-e228
doi:10.1016/j.jacc.2014.09.017Beltrame JF, Crea F, Kaski JC, et al. International standardization of diagnostic criteria for vasospastic angina. Eur Heart J. 2017;38(33):2565-2568
doi:10.1093/eurheartj/ehv351Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119-177
doi:10.1093/eurheartj/ehx393Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477
doi:10.1093/eurheartj/ehz425Münzel T, Gori T, Bruno RM, Taddei S. Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J. 2010;31(22):2741-2748
doi:10.1093/eurheartj/ehq396Cheitlin MD, Hutter AM Jr, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol. 1999;33(1):273-282
doi:10.1016/S0735-1097(98)00656-1Thadani U. Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure. Cardiovasc Drugs Ther. 1997;11(4):515-530
doi:10.1007/BF00053031